Laengdevaekst hos börn, der har astma og er i behandling med inhalerede glukokortikoider
Engelsk titel: Longitudinal growth in children with asthma treated with inhaled glucocorticoids
Läs online
Författare:
Gradman J
;
Wolthers OD
Email: akk.odws@dadlnet.dk
Språk: Dan
Antal referenser: 37
Dokumenttyp:
Översikt
UI-nummer: 06021735
Sammanfattning
Randomised, double-blind studies with a knemometer have shown that the risk of inhaled glucocorticoid-induced growth suppression depends on dose, administration regimen, delivery device and specific glucocorticoid. Dry-powder beclomethasone dipropionate, 300-400 µ g daily, and budesonide, 400 µ g daily, suppress height growth rate by 20-25% during the first year of treatment, whereas lower doses of budesonide and fluticasone propionate do not affect growth rate. Available assessments of final height are flawed by poor compliance rates. Children with asthma on continuous treatment with inhaled glucocorticoids should have their height measured at six-month intervals. In the case of growth deviation, they should be referred for evaluation.